NATCO Pharma Ltd has successfully opposed a patent application in India that covers the composition of Glatiramer Acetate, the generic version of Teva Pharmaceutical Industries' Copaxone. The patent application was submitted to the Indian Patent Office (New Delhi) by Yeda Research & Development Company, which licensed the Glatiramer Acetate product to Teva.
Glatiramer Acetate, marketed in pre-filled syringes, is used to treat multiple sclerosis (MS). NATCO has successfully commercialized its Glatiramer Acetate product in India and the Ukraine. NATCO challenged the Yeda patent application in the Indian Patent Office on several grounds including that it was obvious over the prior art. The Patent Office agreed with NATCO's arguments and refused to grant the application because of "obviousness and lack of inventiveness” over the prior art.
0 comments:
Post a Comment